| Literature DB >> 32976362 |
Seth Kalichman1, Ellen Banas, Moira Kalichman1, Sarah Dewing2, Karen Jennings3, Johann Daniels4, Marcel Berteler4, Catherine Mathews2.
Abstract
BACKGROUND: Evidence-based interventions are needed to stem sexually transmitted infections (STIs). Clinic-delivered counseling remains an important avenue for effective STI prevention.Entities:
Mesh:
Year: 2021 PMID: 32976362 PMCID: PMC7886347 DOI: 10.1097/OLQ.0000000000001295
Source DB: PubMed Journal: Sex Transm Dis ISSN: 0148-5717 Impact factor: 3.868
Figure 1Flow of participants through the 3-arm randomized trial.
Baseline Characteristics of Trial Participants Allocated to the 3 Intervention Conditions
| Health Education | Risk Reduction | Enhanced Partner Notification | ||||
|---|---|---|---|---|---|---|
| n | % | n | % | n | % | |
| Women | 173 | 50 | 174 | 51 | 175 | 50 |
| Men | 177 | 50 | 176 | 49 | 175 | 50 |
| MSM | 3 | 1 | 6 | 2 | 5 | 2 |
| Identified race as Black/African | 341 | 97 | 344 | 98 | 340 | 97 |
| Men circumcised | 147 | 84 | 151 | 85 | 157 | 90 |
| Currently married | 32 | 9 | 24 | 7 | 23 | 7 |
| Living with a partner | 60 | 19 | 66 | 20 | 64 | 20 |
| High school completion | 150 | 42 | 172 | 49 | 151 | 43 |
| HIV positive | 73 | 23 | 66 | 20 | 66 | 20 |
| Hazardous alcohol use* | 213 | 61 | 240 | 69 | 232 | 66 |
| Any drug use | 77 | 22 | 82 | 23 | 79 | 23 |
| Mean | SD | Mean | SD | Mean | SD | |
| Age, y | 29.4 | 7.8 | 28.6 | 7.2 | 29.5 | 6.9 |
| No. sex partners, past 3 mo | ||||||
| Main partners | 0.9 | 0.3 | 0.9 | 0.4 | 1.0 | 0.4 |
| Casual partners | 0.8 | 1.2 | 0.8 | 1.2 | 0.8 | 1.4 |
| Once-off partners | 0.4 | 1.0 | 0.5 | 1.4 | 0.5 | 1.9 |
| Total partners | 2.1 | 1.6 | 2.3 | 1.9 | 2.3 | 3.1 |
There were no significance between conditions on baseline characteristics.
*Hazardous alcohol use defined by Alcohol Use Disorders Identification Test for Consumption scores greater the 3 for men and greater than 2 for women.
Sexual Behaviors and Condom Use Outcomes for the 3 Intervention Conditions
| Health Education | Risk Reduction | Enhanced Partner Notification | Condition | Condition × Gender | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| n | % | n | % | n | % | Wald χ2 | Wald χ2 | |||
| Any return STI visits, 12 mo | ||||||||||
| All participants | 91 | 26 | 81 | 23 | 81 | 23 | 1.44 | 0.48 | 6.02 | 0.04 |
| Men | 51 | 29 | 54 | 30 | 40 | 23 | ||||
| Women | 40 | 23 | 27 | 16 | 41 | 23 | ||||
| No. return STI visits, 12 mo | Mean | SE | Mean | SE | Mean | SE | ||||
| All participants | 0.32 | 0.03 | 0.27 | 0.03 | 0.29 | 0.03 | 1.06 | 0.58 | 3.91 | 0.14 |
| Men | 0.38 | 0.05 | 0.38 | 0.04 | 0.29 | 0.04 | ||||
| Women | 0.27 | 0.04 | 0.20 | 0.04 | 0.29 | 0.04 | ||||
| Vaginal sex occasions | Mean | SD | Mean | SD | Mean | SD | ||||
| Baseline | 28.6 | 41.7 | 33.7 | 69.9 | 29.7 | 48.7 | 1.79 | 0.40 | 0.79 | 0.67 |
| Men | 35.7 | 5.4 | 36.4 | 80.2 | 34.3 | 61.5 | ||||
| Women | 21.1 | 26.3 | 30.8 | 57.1 | 25.0 | 29.7 | ||||
| 3 mo | ||||||||||
| All participants | 22.0 | 25.6 | 31.3 | 70.5 | 22.4 | 30.5 | ||||
| Men | 24.8 | 26.7 | 39.0 | 89.6 | 25.4 | 36.1 | ||||
| Women | 19.2 | 24.3 | 23.0 | 40.0 | 19.3 | 23.2 | ||||
| 6 mo | ||||||||||
| All participants | 27.9 | 42.4 | 31.0 | 68.4 | 28.3 | 38.1 | ||||
| Men | 35.5 | 53.9 | 39.0 | 91.3 | 30.1 | 38.3 | ||||
| Women | 20.4 | 24.5 | 22.8 | 28.8 | 26.5 | 38.0 | ||||
| 9 mo | ||||||||||
| All participants | 33.5 | 44.7 | 40.0 | 76.3 | 32.3 | 69.4 | ||||
| Men | 40.0 | 48.2 | 47.5 | 98.5 | 37.7 | 91.2 | ||||
| Women | 27.1 | 40.0 | 32.3 | 42.1 | 27.0 | 37.6 | ||||
| Vaginal sex, % condom use | ||||||||||
| Baseline | ||||||||||
| All participants | 40.8 | 33.8 | 41.1 | 34.7 | 40.1 | 34.3 | 10.16 | 0.01 | 1.63 | 0.44 |
| Men | 40.2 | 31.8 | 42.2 | 35.1 | 42.1 | 32.7 | ||||
| Women | 41.4 | 35.9 | 39.8 | 34.3 | 38.0 | 35.9 | ||||
| 3 mo | ||||||||||
| All participants | 53.9 | 40.1 | 60.0 | 40.4 | 50.9 | 39.6 | ||||
| Men | 54.1 | 40.1 | 61.0 | 40.1 | 52.6 | 38.8 | ||||
| Women | 53.4 | 41.5 | 58.9 | 40.9 | 49.1 | 40.4 | ||||
| 6 mo | ||||||||||
| All participants | 49.5 | 40.8 | 59.5 | 39.5 | 52.2 | 41.2 | ||||
| Men | 45.7 | 41.0 | 61.7 | 39.4 | 53.7 | 39.6 | ||||
| Women | 53.3 | 40.5 | 57.4 | 39.7 | 50.7 | 42.9 | ||||
| 9 mo | ||||||||||
| All participants | 50.2 | 40.2 | 56.3 | 40.9 | 51.6 | 41.8 | ||||
| Men | 45.6 | 38.4 | 56.2 | 39.3 | 50.7 | 41.1 | ||||
| Women | 54.9 | 41.5 | 56.5 | 42.7 | 52.5 | 42.7 | ||||
| Anal sex occasions | ||||||||||
| Baseline | ||||||||||
| All participants | 0.8 | 6.4 | 1.0 | 6.9 | 0.4 | 1.8 | 0.62 | 0.73 | 4.21 | 0.12 |
| Men | 0.6 | 3.1 | 1.5 | 8.5 | 0.5 | 2.3 | ||||
| Women | 1.1 | 8.7 | 0.6 | 4.6 | 0.2 | 0.8 | ||||
| 3 mo | ||||||||||
| All participants | 0.4 | 2.7 | 1.2 | 8.2 | 0.7 | 6.3 | ||||
| Men | 0.5 | 3.3 | 1.8 | 10.4 | 1.0 | 8.3 | ||||
| Women | 0.4 | 1.8 | 0.6 | 4.7 | 0.5 | 3.1 | ||||
| 6 mo | ||||||||||
| All participants | 0.4 | 2.9 | 0.5 | 3.2 | 0.7 | 4.0 | ||||
| Men | 0.4 | 3.6 | 0.8 | 4.5 | 1.1 | 5.3 | ||||
| Women | 0.3 | 2.0 | 0.2 | 1.0 | 0.3 | 1.8 | ||||
| 9 mo | ||||||||||
| All participants | 0.5 | 2.6 | 0.3 | 2.2 | 0.6 | 6.3 | ||||
| Men | 0.5 | 3.3 | 0.6 | 3.1 | 0.1 | 0.9 | ||||
| Women | 0.5 | 1.8 | 0.1 | 0.7 | 1.1 | 8.7 | ||||
| Anal sex, % condom use | ||||||||||
| Baseline | ||||||||||
| All participants | 20.6 | 34.5 | 27.3 | 39.1 | 30.2 | 40.9 | 1.21 | 0.54 | 4.59 | 0.10 |
| Men | 24.5 | 38.5 | 32.1 | 42.9 | 32.5 | 38.9 | ||||
| Women | 14.4 | 26.8 | 20.1 | 32.4 | 27.4 | 43.9 | ||||
| 3 mo | ||||||||||
| All participants | 42.3 | 44.6 | 46.0 | 44.7 | 36.8 | 44.1 | ||||
| Men | 51.3 | 45.7 | 52.5 | 43.2 | 39.0 | 42.9 | ||||
| Women | 30.2 | 40.3 | 34.8 | 45.4 | 33.9 | 46.0 | ||||
| 6 mo | ||||||||||
| All participants | 40.5 | 42.2 | 49.6 | 44.4 | 48.5 | 45.5 | ||||
| Men | 43.5 | 42.7 | 54.3 | 43.7 | 53.2 | 44.7 | ||||
| Women | 36.9 | 41.8 | 43.1 | 44.9 | 41.7 | 46.3 | ||||
| 9 mo | ||||||||||
| All participants | 44.0 | 44.2 | 56.2 | 43.8 | 51.9 | 46.7 | ||||
| Men | 41.7 | 42.4 | 57.4 | 42.6 | 54.9 | 45.9 | ||||
| Women | 46.9 | 46.6 | 54.5 | 45.7 | 48.8 | 47.6 | ||||
Figure 2Percentages of male and female participants who returned for an STI clinic visit within 12 months after receiving the 3 counseling conditions.
Figure 3Mean use of condoms during vaginal intercourse during assessment periods for participants receiving the 3 counseling conditions.
STI Knowledge, HIV Stigma, and Prevention Self-Efficacy Outcomes for the 3 Intervention Conditions
| Health Education | Risk Reduction | Enhanced Partner Notification | Condition | Condition × Gender | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Mean | SD | Mean | SD | Mean | SD | Wald χ2 | Wald χ2 | |||
| STI knowledge | ||||||||||
| Baseline | ||||||||||
| All participants | 2.8 | 1.0 | 2.8 | 0.9 | 2.6 | 0.9 | 4.59 | 0.10 | 4.37 | 0.11 |
| Men | 2.8 | 1.0 | 2.9 | 0.9 | 2.6 | 0.9 | ||||
| Women | 2.7 | 1.0 | 2.8 | 1.0 | 2.7 | 0.9 | ||||
| 3 mo | ||||||||||
| All participants | 3.0 | 0.9 | 3.1 | 0.9 | 3.1 | 0.9 | ||||
| Men | 3.1 | 0.9 | 3.0 | 0.9 | 3.0 | 0.8 | ||||
| Women | 2.9 | 0.8 | 3.2 | 0.8 | 3.1 | 0.9 | ||||
| 6 mo | ||||||||||
| All participants | 3.1 | 0.9 | 3.1 | 0.8 | 3.2 | 0.8 | ||||
| Men | 3.2 | 0.8 | 3.1 | 0.9 | 3.1 | 0.7 | ||||
| Women | 3.1 | 0.9 | 3.2 | 0.8 | 3.3 | 0.8 | ||||
| 9 mo | ||||||||||
| All participants | 3.1 | 0.8 | 3.2 | 0.8 | 3.2 | 0.8 | ||||
| Men | 3.1 | 0.9 | 3.2 | 0.8 | 3.1 | 0.9 | ||||
| Women | 3.1 | 0.8 | 3.1 | 0.8 | 3.2 | 0.8 | ||||
| HIV stigma | ||||||||||
| Baseline | ||||||||||
| All participants | 2.3 | 0.5 | 2.3 | 0.4 | 2.3 | 0.4 | 4.48 | 0.10 | 0.77 | 0.68 |
| Men | 2.3 | 0.4 | 2.3 | 0.5 | 2.3 | 0.04 | ||||
| Women | 2.3 | 0.04 | 2.3 | 0.4 | 2.3 | 0.4 | ||||
| 3 mo | ||||||||||
| All participants | 1.2 | 0.4 | 1.1 | 0.3 | 1.2 | 0.4 | ||||
| Men | 1.2 | 0.4 | 1.1 | 0.4 | 1.2 | 0.4 | ||||
| Women | 1.2 | 0.4 | 1.1 | 0.3 | 1.2 | 0.3 | ||||
| 6 mo | ||||||||||
| All participants | 1.2 | 0.3 | 1.1 | 0.3 | 1.1 | 0.3 | ||||
| Men | 1.1 | 0.3 | 1.1 | 0.4 | 1.1 | 0.3 | ||||
| Women | 1.2 | 0.4 | 1.1 | 0.3 | 1.1 | 0.2 | ||||
| 9 mo | ||||||||||
| All participants | 1.1 | 0.3 | 1.1 | 0.3 | 1.1 | 0.3 | ||||
| Men | 1.2 | 0.3 | 1.1 | 0.4 | 1.1 | 0.4 | ||||
| Women | 1.1 | 0.3 | 1.1 | 0.2 | 1.1 | 0.2 | ||||
| Prevention self-efficacy | ||||||||||
| Baseline | ||||||||||
| All participants | 8.1 | 1.6 | 8.0 | 1.7 | 7.9 | 1.7 | 5.17 | 0.07 | 0.12 | 0.94 |
| Men | 8.2 | 1.5 | 8.0 | 1.6 | 7.9 | 1.8 | ||||
| Women | 7.9 | 1.7 | 8.1 | 1.9 | 8.0 | 1.7 | ||||
| 3 mo | ||||||||||
| All participants | 8.1 | 1.7 | 8.3 | 1.6 | 8.4 | 1.5 | ||||
| Men | 8.1 | 1.7 | 8.2 | 1.6 | 8.4 | 1.5 | ||||
| Women | 8.1 | 1.8 | 8.3 | 1.7 | 8.5 | 1.5 | ||||
| 6 mo | ||||||||||
| All participants | 8.2 | 1.6 | 8.3 | 1.6 | 8.4 | 1.6 | ||||
| Men | 8.1 | 1.7 | 8.3 | 1.5 | 8.4 | 1.6 | ||||
| Women | 8.3 | 1.5 | 8.3 | 1.6 | 8.3 | 1.7 | ||||
| 9 mo | ||||||||||
| All participants | 8.1 | 1.8 | 8.4 | 1.6 | 8.4 | 1.7 | ||||
| Men | 8.2 | 1.7 | 8.6 | 1.4 | 8.5 | 1.6 | ||||
| Women | 8.2 | 1.7 | 8.5 | 1.5 | 8.4 | 1.7 | ||||